Highlights
The WAYFINDER trial provides critical evidence for the use of tezepelumab in reducing systemic steroid exposure in patients with severe asthma. Key findings include:
- Approximately 90% of patients achieved a maintenance oral corticosteroid (OCS) dose of 5 mg per day or less by week 52.
- Complete OCS discontinuation was achieved by 50.3% of participants at one year, representing a significant milestone in asthma management.
- Efficacy in OCS reduction was observed across all patient subgroups, independent of baseline blood eosinophil counts (BEC), fractional exhaled nitric oxide (FeNO), or allergy status.
- The safety profile remained consistent with previous tezepelumab trials, with no new safety signals identified despite the tapering of systemic steroids.
